FatCamera/Getty Images(NEW YORK) A new medication just approved by the U.S. Food and Drug Administration could revolutionize the treatment of postpartum depression, a condition that affects as many as 1 in 8 women who have recently given birth.
The medication, zuranolone, to be sold under the brand name Zurzuvae, is the first oral pill to ever be approved by the FDA to treat postpartum depression, a depression that occurs after having a baby.
"Postpartum depression is a serious and potentially life-threatening condition in which women experience sadness, guilt, worthlessness even, in severe cases, thoughts of harming themselves or their child. And, because postpartum depression can disrupt the maternal-infant bond, it can also have consequences for the child s physical and emotional development," Dr. Tiffany R. Farchione, director of the Division of Psychiatry at the FDA s Center for Drug Evaluation and Research, said in a statement. "Having access to an oral medic
United-states
America
American
Darien-sutton
Tiffanyr-farchione
Us-centers-for-disease
Journal-of-the-american-medical-association-psychiatry
National-suicide-lifeline
Division-of-psychiatry
Drug-administration
Drug-enforcement-administration
Drug-evaluation